17.81
전일 마감가:
$17.43
열려 있는:
$17.49
하루 거래량:
5.58M
Relative Volume:
0.98
시가총액:
$8.85B
수익:
$4.45B
순이익/손실:
$205.00M
주가수익비율:
44.52
EPS:
0.4
순현금흐름:
$372.00M
1주 성능:
+27.67%
1개월 성능:
+19.53%
6개월 성능:
+52.74%
1년 성능:
+27.76%
엘란코 Stock (ELAN) Company Profile
명칭
Elanco Animal Health Inc
전화
877-352-6261
주소
2500 INNOVATION WAY, GREENFIELD
ELAN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ELAN
Elanco Animal Health Inc
|
17.81 | 8.66B | 4.45B | 205.00M | 372.00M | 0.40 |
![]()
ZTS
Zoetis Inc
|
152.44 | 66.38B | 9.39B | 2.61B | 2.22B | 5.81 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.20B | 29.98B | 958.27M | 5.31B | 0.2964 |
![]()
HLN
Haleon Plc Adr
|
9.69 | 42.99B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 19.04B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
309.72 | 13.63B | 2.99B | 1.21B | 1.13B | 25.06 |
엘란코 Stock (ELAN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-17 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2025-06-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
2024-12-09 | 개시 | UBS | Buy |
2024-12-02 | 개시 | Leerink Partners | Market Perform |
2024-09-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2024-01-05 | 업그레이드 | Stifel | Hold → Buy |
2023-12-19 | 개시 | Jefferies | Buy |
2023-12-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2023-12-07 | 개시 | Exane BNP Paribas | Outperform |
2023-04-20 | 업그레이드 | Barclays | Equal Weight → Overweight |
2022-08-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2022-08-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2022-07-21 | 다운그레이드 | Goldman | Buy → Sell |
2022-07-12 | 개시 | Piper Sandler | Neutral |
2021-11-18 | 개시 | Morgan Stanley | Overweight |
2021-10-28 | 다운그레이드 | Stifel | Buy → Hold |
2021-08-05 | 재개 | Credit Suisse | Outperform |
2021-06-15 | 업그레이드 | Cleveland Research | Underperform → Neutral |
2021-05-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
2021-05-11 | 업그레이드 | Gabelli & Co | Hold → Buy |
2021-04-15 | 개시 | Stifel | Buy |
2021-03-22 | 다운그레이드 | Gabelli & Co | Buy → Hold |
2021-02-26 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2020-12-09 | 다운그레이드 | Argus | Buy → Hold |
2020-11-09 | 다운그레이드 | Barclays | Overweight → Underweight |
2020-08-20 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2020-08-13 | 재개 | Credit Suisse | Neutral |
2020-08-04 | 재개 | Goldman | Buy |
2020-07-27 | 다운그레이드 | Cleveland Research | Neutral → Underperform |
2020-04-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-01-10 | 개시 | Raymond James | Mkt Perform |
2019-12-19 | 업그레이드 | BofA/Merrill | Neutral → Buy |
2019-11-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2019-09-23 | 개시 | Barclays | Overweight |
2019-08-26 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2019-08-15 | 업그레이드 | UBS | Sell → Neutral |
2019-05-23 | 개시 | Guggenheim | Neutral |
2019-03-18 | 업그레이드 | BofA/Merrill | Neutral → Buy |
2019-03-13 | 재개 | Morgan Stanley | Equal-Weight |
2019-02-12 | 개시 | William Blair | Mkt Perform |
2019-01-23 | 개시 | UBS | Sell |
2019-01-15 | 개시 | Argus | Buy |
2018-10-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
엘란코 주식(ELAN)의 최신 뉴스
Elanco spearheads Nutrition Secure Indianapolis initiative to provide food aid - Inside INdiana Business
Dogs Vaccines Market Exclusive Report with Detailed Study - openPR.com
Elanco Animal Health Posts Robust Q2 Earnings, Exceeds Guidance with Strong Organic Growth and Innovation - AInvest
Elanco’s Q2 2025 Return to Profitability Signals Growth - Zenopa
Leerink Partners Keeps Buy Rating on Elanco Animal Health with $20 Price Target - AInvest
ELAN Q2 Deep Dive: Innovation and Execution Drive Raised Full-Year Outlook - FinancialContent
Elanco Animal Health (NYSE:ELAN) Releases Q3 2025 Earnings Guidance - MarketBeat
Price Consolidation Hints at Upcoming Move in Elanco Animal Health IncorporatedReversal Alert Based on RSI Indicator Confirmed - metal.it
Elanco (ELAN) Jumps 19.7% to Record High on Earnings Boost - MSN
Elanco Animal Health Surges 9% on Q2 Results and Optimistic Full-Year Forecast - AInvest
Elanco Animal Health: Analyst Sentiment Analysis and 12-Month Price Targets - AInvest
Elanco Animal Health Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Elanco Animal Health Incorporated (NYSE:ELAN) Q2 2025 Earnings Call Transcript - Insider Monkey
Elanco Animal Health (ELAN) Gets a Buy from Bank of America Securities - The Globe and Mail
Elanco Animal Health Reports Strong Q2 2025 Results - The Globe and Mail
Chart based analysis of Elanco Animal Health Incorporated trendsTrend Confirmation Scanner with Entry Focus - Newser
ICYMI: Elanco Shares Jump After 2Q Beat-and-Raise Results - iHeart
Elanco Puppy Virus Treatment Expanded With USDA Approval - InkFreeNews.com
UBS Raises PT to $19 for Elanco Animal Health Amid Bullish Outlook - AInvest
A Quick Look at Today's Ratings for Elanco Animal Health(ELAN.US), With a Forecast Between $15 to $21 - 富途牛牛
An Intrinsic Calculation For Elanco Animal Health Incorporated (NYSE:ELAN) Suggests It's 36% Undervalued - Yahoo Finance
Elanco Animal Health shares fall 1.40% premarket after beating Q2 revenue estimates and raising FY guidance. - AInvest
What institutional flow reveals about Elanco Animal Health IncorporatedStrong Buy Signal Summary with Entry Zone - Newser
Elanco Animal Health Inc (ELAN) Q2 2025 Earnings Call Highlights: Strong Pet Health Growth and ... By GuruFocus - Investing.com Canada
Elanco Animal Health 2025 Q2 Earnings Strong Performance as Net Income Surges 122% - AInvest
Elanco Raises 2025 Innovation Revenue Outlook to $720M-$800M, Signals Margin Expansion Through New Launches. - AInvest
10 Hot Stocks Making Winning Look Easy - Insider Monkey
Elanco (ELAN) Q2 Revenue Jumps 5% - AOL.com
Elanco's Q2 2025 Earnings Call: Unraveling Key Contradictions in FX Impact, Innovation Growth, and Margin Dynamics - AInvest
Elanco Animal Health Q2 2025: Innovation-Driven Growth and Accelerated Deleveraging Justify a Buy Rating - AInvest
Elanco Animal Health shares fall 1.55% after-hours despite beating Q2 revenue estimates and raising FY guidance. - AInvest
Elanco's Q2 Revenue Exceeds Expectations, Raises Full-Year Guidance - AInvest
Elanco bolsters parvovirus treatment with new approval - Inside INdiana Business
Elanco (NYSE:ELAN) Delivers Impressive Q2, Stock Jumps 15.4% - Yahoo Finance
Elanco Animal Health Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Elanco Animal Health beats Q2 2025 expectations By Investing.com - Investing.com Canada
Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Beat Estimates - MSN
Why Is Elanco Animal Health Stock Soaring Thursday?Elanco Animal Health (NYSE:ELAN) - Benzinga
Elanco Animal Health stock hits 52-week high at $15.79 By Investing.com - Investing.com Canada
Elanco Animal Health (ELAN) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Elanco Animal Health Inc SEC 10-Q Report - TradingView
Elanco stock spikes after Q2 beat, guidance raise (ELAN:NYSE) - Seeking Alpha
Elanco Animal Health’s Stock Faces Unusual Movement - TipRanks
Elanco (ELAN) Q2 Revenue Jumps 5% - The Motley Fool
Elanco Animal Health earnings beat by $0.06, revenue topped estimates - Investing.com Canada
Elanco Q2 2025 slides: 8% organic growth drives raised guidance despite headwinds - Investing.com Canada
Elanco Animal Health beats Q2 revenue estimates, raises FY guidance - MarketScreener
Elanco Animal Health Reports Second Quarter 2025 Results - TradingView
Elanco raises full-year guidance on strength of newest products - Indianapolis Business Journal
Curious about Elanco Animal Health (ELAN) Q2 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
What To Expect From Elanco’s (ELAN) Q2 Earnings - Yahoo Finance
엘란코 (ELAN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
엘란코 주식 (ELAN) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Kurzius Lawrence Erik | Director |
Mar 07 '25 |
Buy |
10.90 |
10,000 |
109,000 |
101,459 |
Kurzius Lawrence Erik | Director |
Mar 11 '25 |
Buy |
10.20 |
10,000 |
102,000 |
111,459 |
HOOVER R DAVID | Director |
Mar 05 '25 |
Buy |
10.90 |
25,000 |
272,558 |
210,000 |
Harrington Michael J | Director |
Aug 22 '24 |
Buy |
14.85 |
3,500 |
51,974 |
81,094 |
자본화:
|
볼륨(24시간):